[Update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]

Ann Pathol. 2010 Oct;30(5):357-73. doi: 10.1016/j.annpat.2010.07.001. Epub 2010 Oct 16.
[Article in French]

Abstract

In Europe, patients who may benefit from an HER2 targeted drug are currently selected by immunohistochemistry (IHC). In situ hybridization (ISH) techniques should be used for complementary assessment of ambiguous 2+ IHC cases and for the calibration of the IHC technique. Eligibility to an HER2 target treatment is defined by an HER2 positive status being IHC test 3+ or 2+ amplified. Reliable detection of HER2 status is essential to the appropriate usage of HER2 targeted drugs because its specificity is limited to tumors overexpressing HER2. It is essential that the IHC evaluation of the HER2 status of a mammary carcinoma is optimized and reliable. This GEFPICS' guidelines look over the different steps of the IHC technique, the controls and, the rules for interpretation. Once acquired, this knowledge must be perpetuated by the observation of rules of good technical practice (internal and external controls, quality assurance programs).

Publication types

  • Practice Guideline

MeSH terms

  • Breast Neoplasms / chemistry*
  • Breast Neoplasms / pathology*
  • France
  • Humans
  • Immunohistochemistry / standards
  • In Situ Hybridization / standards
  • Quality Control
  • Receptor, ErbB-2 / analysis*
  • Records

Substances

  • ERBB2 protein, human
  • Receptor, ErbB-2